leukemia

(redirected from Chronic myelomonocytic leukemia)
Also found in: Dictionary, Medical, Acronyms, Encyclopedia, Wikipedia.
References in periodicals archive ?
Philadelphia-negative (Ph-) chronic myeloid leukemia (CML): Comparison with Ph+ CML and chronic myelomonocytic leukemia.
In a Letter to the Editor entitled "Molecular profiling of chronic myelomonocytic leukemia reveals diverse mutations in >80% of patients with TET2 and EZH2 being of high prognostic relevance" published in the February 22, 2011 issue of Nature LEUKEMIA (www.
This mutation has also been found in patients with non-classic MPDs such as refractory anemia with ringed sideroblasts associated with thrombocytosis (RARS-T), chronic neutrophilic leukemia (CNL), atypical chronic myeloid leukemia (CML) and chronic myelomonocytic leukemia (CMML) at incidences of 50%, 20%, 20% and 3%, respectively.
With the possibility of exploring KB003 in chronic myelomonocytic leukemia, an orphan oncology indication, we believe we have the potential for a very exciting oncology pipeline and are looking forward to advancing these programs in the clinic.
These subtypes include: refractory anemia (RA) or refractory anemia with ringed sideroblasts (RARS) if accompanied by neutropenia or thrombocytopenia or requiring transfusions; refractory anemia with excess blasts (RAEB), refractory anemia with excess blasts in transformation (RAEB-T), and chronic myelomonocytic leukemia (CMMoL).
KaloBios is currently evaluating the potential of this compound in oncology indications where GM-CSF may play a key role such as chronic myelomonocytic leukemia (CMML) to determine if there is adequate scientific rationale to commence clinical evaluation of KB003 in an oncology setting.
Nasdaq:MOGN), a biopharmaceutical company focused in oncology and acute care, announced the publication in the journal Blood of a phase 2 study that evaluated three schedules of low dose regimens for Dacogen[TM] (decitabine) for Injection in patients with myelodysplastic syndromes (MDS) and chronic myelomonocytic leukemia (CMML).
In a separate presentation, researchers showed pacritinib demonstrated a unique kinome profile that supports potential role in modulating tumor microenvironments in blood-related cancers, including AML, myelodysplastic syndromes (MDS), chronic myelomonocytic leukemia (CMML) and chronic lymphocytic leukemia (CLL).
Efficacy of Dacogen in the Treatment of Patients with Chronic Myelomonocytic Leukemia (CMML) (Abstracts 2652 and 2655)
Full browser ?